KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Pain relief by targeting nonrestorative sleep in fibromyalgia: a phase 3 randomized trial of bedtime sublingual cyclobenzaprine.

Seth Lederman, Lesley M Arnold, Ben Vaughn, Jean M Engels, Mary Kelley, Gregory M Sullivan

Pain Med 27(1) 86-94

PMID40627411
PMCIDPMC12773742
DOI10.1093/pm/pnaf089
发表日期2025-07-08
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。
摘要

摘要

OBJECTIVE: Fibromyalgia is the prototypic nociplastic chronic pain syndrome, characterized by widespread pain, nonrestorative sleep, and fatigue. We evaluated efficacy and safety of bedtime TNX-102 SL (sublingual cyclobenzaprine) 5.6 mg for treatment of fibromyalgia. METHODS: This phase 3, double-blind, multicenter, placebo-controlled trial randomized patients 1:1 to once-nightly TNX-102 SL 2.8 mg for 2 weeks, followed by 5.6 mg for 12 weeks, or to matching placebo (NCT05273749). The primary endpoint was change from baseline at week 14 in weekly average of daily diary pain intensity scores. Secondary endpoints included Patient Global Impression of Change, Fibromyalgia Impact Questionnaire (Revised) Symptoms and Function domains, Patient-Reported Outcomes Measurement Information System instruments for Sleep Disturbance and Fatigue, and daily diary sleep quality scores. RESULTS: Overall, 81.0% (n = 187/231) and 79.6% (n = 179/225) of patients receiving TNX-102 SL and placebo completed the trial, respectively. Treatment with TNX-102 SL vs placebo was associated with significantly greater reductions in the primary pain endpoint (P < .001; mean [SE], -1.8 [0.12] vs -1.2 [0.12]) and in each of the 6 secondary endpoints (P ≤ .001; all). The most common systemic treatment-emergent adverse events (TEAEs) with TNX-102 SL and placebo were COVID-19 (4.3% vs 3.1%, respectively), headache (3.0% vs 1.8%), and somnolence (3.0% vs 1.3%); the most common TEAEs overall were local administration-site reactions including oral hypoesthesia (23.4% vs 0.4%), product taste abnormal (11.3% vs 0.9%), and oral paresthesia (6.9% vs 0.9%), which were transient and self-limited. CONCLUSION: Bedtime TNX-102 SL treatment was associated with significant improvements in fibromyalgia symptoms and function and was well tolerated. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov/study/NCT05273749, first patient screened March 21, 2022.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Patient disposition. AE, adverse event; mITT, modified intent-to-treat; SAF, safety; SL, sublingual. *One patient who received placebo was inadvertently randomized and is included in the SAF population but not in the mITT population.
非 KM Figure
Figure 2Figure 2. Primary efficacy endpoint. LS mean (SE) change from baseline in the weekly average of daily pain NRS intensity scores. No. of patients indicates patients with available data at each time point; multiple imputation was used to account for missing data. LS, least-squares; NRS, numeric rating scale; SL, sublingual. * P < .001; † P < .01 (uncorrected).
非 KM Figure
Figure 3Figure 3. Key secondary endpoints. (A) Percentage of PGIC responders (ie, patients reporting “much improved” or “very much improved”) and LS mean (SE) change from baseline in (B) FIQR Symptoms score, (C) PROMIS Sleep Disturbance T-score, and (D) PROMIS Fatigue T-score. No. of patients indicates patients with available data at each time point; missing data were considered nonresponse for A, whereas multiple imputation was used to account for missing data for B-D. FIQR, Fibromyalgia Impact Questionnaire (Revised); LS, least-squares; PROMIS, Patient-Reported Outcomes Measurement Information System; PGIC, Patient Global Impression of Change; SL, sublingual. * P < .001; † P < .01 (uncorrected).
非 KM Figure